Estradiol transdermal - Allergan

Drug Profile

Estradiol transdermal - Allergan

Alternative Names: Alora; Estran; TTI 102

Latest Information Update: 15 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Watson Laboratories
  • Developer Allergan
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 20 Aug 2013 Biomarkers information updated
  • 15 Jan 2003 A study has been added to the adverse events and Musculoskeletal and Women's Health therapeutic trials sections
  • 05 Apr 2002 Registered for Postmenopausal osteoporosis prevention in USA plus approved as a low dose 0.025 mg/day product (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top